Radiolabeling of lacosamide using highly purified rhenium-188 as a prospective brain theranostic agent

[1]  I. T. Ibrahim,et al.  Preparation of 186Re-Cefixime as a Potential Diagnostic and Therapeutic Agent for Bacterial Infection , 2019, Egyptian Journal of Radiation Sciences and Applications.

[2]  H. Talaat,et al.  Preparation and Biodistribution of 99mTc-Trazodone as a Brain Imaging Probe , 2019, Radiochemistry.

[3]  A. El-Sadek,et al.  Preparation and characterization of zirconium silico188W-tungstate as a base material for 188W/188Re generator. , 2018, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[4]  A. El-Sadek,et al.  Zirconium silicotungstate matrix as a prospective sorbent material for the preparation of 113Sn/113mIn generator , 2018, Journal of Radioanalytical and Nuclear Chemistry.

[5]  G. Gigli,et al.  Pharmacokinetic drug evaluation of lacosamide for the treatment of partial-onset seizures , 2017, Expert opinion on drug metabolism & toxicology.

[6]  E. Elmaghraby.  Investigation of epi-thermal shape-parameter needed for precision analysis of activation , 2017 .

[7]  S. K. Tripathy,et al.  Two fluid anisotropic dark energy models in a scale invariant theory , 2015, 1503.05109.

[8]  M. A. Motaleb,et al.  Preparation and biological evaluation of (99m)Tc-ropinirole as a novel radiopharmaceutical for brain imaging. , 2016, Journal of labelled compounds & radiopharmaceuticals.

[9]  H. Talaat,et al.  Preparation, characterization and evaluation of (186) Re-idarubicin: a novel agent for diagnosis and treatment of hepatocellular carcinoma. , 2016, Journal of labelled compounds & radiopharmaceuticals.

[10]  Sarah M. Wilson,et al.  Specific Binding of Lacosamide to Collapsin Response Mediator Protein 2 (CRMP2) and Direct Impairment of its Canonical Function: Implications for the Therapeutic Potential of Lacosamide , 2015, Molecular Neurobiology.

[11]  E. E. Vincent,et al.  Glycogen Synthase Kinase 3 Protein Kinase Activity Is Frequently Elevated in Human Non-Small Cell Lung Carcinoma and Supports Tumour Cell Proliferation , 2014, PloS one.

[12]  K. Yavari,et al.  Preparation and radiolabeling of a lyophilized (kit) formulation of DOTA-rituximab with 90Y and 111In for domestic radioimmunotherapy and radioscintigraphy of Non-Hodgkin’s Lymphoma , 2014, DARU Journal of Pharmaceutical Sciences.

[13]  J. Couchman,et al.  Phosphorylation and mRNA Splicing of Collapsin Response Mediator Protein-2 Determine Inhibition of Rho-associated Protein Kinase (ROCK) II Function in Carcinoma Cell Migration and Invasion* , 2013, The Journal of Biological Chemistry.

[14]  S. Llanos,et al.  Phosphorylated tubulin adaptor protein CRMP‐2 as prognostic marker and candidate therapeutic target for NSCLC , 2013, International journal of cancer.

[15]  S. N. Azmi,et al.  Quantitative analysis of cefixime via complexation with palladium(II) in pharmaceutical formulations by spectrophotometry , 2013, Journal of pharmaceutical analysis.

[16]  T. Luo,et al.  Investigation of the local delivery of an intelligent chitosan-based 188Re thermosensitive in situ-forming hydrogel in an orthotopic hepatoma-bearing rat model , 2013, Journal of Radioanalytical and Nuclear Chemistry.

[17]  Yih-Leong Chang,et al.  Phosphorylation of LCRMP-1 by GSK3β Promotes Filopoda Formation, Migration and Invasion Abilities in Lung Cancer Cells , 2012, PloS one.

[18]  Yih-Leong Chang,et al.  The ability of LCRMP-1 to promote cancer invasion by enhancing filopodia formation is antagonized by CRMP-1. , 2011, The Journal of clinical investigation.

[19]  M. R. Mahran,et al.  Synthesis of a 188Re–DTPMP complex using carrier-free 188Re and study of its stability , 2011 .

[20]  S. Vasantharaju,et al.  Development and validation of stability-indicating assay method for lacosamide by RP- HPLC , 2011 .

[21]  V. Chakravarthy,et al.  DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR ESTIMATION OF LACOSAMIDE IN BULK AND ITS PHARMACEUTICAL FORMULATION , 2011 .

[22]  N. Fountain,et al.  Lacosamide for the treatment of partial-onset seizures , 2010 .

[23]  J. Honnorat,et al.  CRMP5 Interacts with Tubulin to Inhibit Neurite Outgrowth, Thereby Modulating the Function of CRMP2 , 2010, The Journal of Neuroscience.

[24]  Ki Duk Park,et al.  In Silico Docking and Electrophysiological Characterization of Lacosamide Binding Sites on Collapsin Response Mediator Protein-2 Identifies a Pocket Important in Modulating Sodium Channel Slow Inactivation* , 2010, The Journal of Biological Chemistry.

[25]  Yih-Leong Chang,et al.  Long form collapsin response mediator protein-1 (LCRMP-1) expression is associated with clinical outcome and lymph node metastasis in non-small cell lung cancer patients. , 2010, Lung cancer.

[26]  I. T. Ibrahim,et al.  Application of 99Mo/99mTc alumina generator in the labeling of metoprolol for diagnostic purposes , 2009 .

[27]  L. Machesky.  Lamellipodia and filopodia in metastasis and invasion , 2008, FEBS letters.

[28]  Jeremy J. W. Chen,et al.  Modulation of the expression of the invasion-suppressor CRMP-1 by cyclooxygenase-2 inhibition via reciprocal regulation of Sp1 and C/EBPα , 2008, Molecular Cancer Therapeutics.

[29]  J. Trobe,et al.  High-titer collapsin response-mediating protein-associated (CRMP-5) paraneoplastic optic neuropathy and Vitritis as the only clinical manifestations in a patient with small cell lung carcinoma. , 2008, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.

[30]  Hua-Chien Chen,et al.  Identification of collapsin response mediator protein‐2 as a potential marker of colorectal carcinoma by comparative analysis of cancer cell secretomes , 2008, Proteomics.

[31]  R. Sheorajpanday,et al.  Small cell lung carcinoma presenting as collapsin response-mediating protein (CRMP) -5 paraneoplastic optic neuropathy. , 2006, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.

[32]  Chi-Ying F. Huang,et al.  Collapsin response mediator protein-1: A novel invasion-suppressor gene , 2003, Clinical & Experimental Metastasis.

[33]  S. Pervez,et al.  188Rhenium-EDTMP: A potential therapeutic bone agent , 2003 .

[34]  M. Noda,et al.  Axonal morphogenesis controlled by antagonistic roles of two CRMP subtypes in microtubule organization , 2003, The European journal of neuroscience.

[35]  S. Pervez,et al.  Preparation of 188Re-labeled hydroxyapatite for radiosynovectomy , 2002 .

[36]  K. Kaibuchi,et al.  CRMP-2 binds to tubulin heterodimers to promote microtubule assembly , 2002, Nature Cell Biology.

[37]  Yih-Leong Chang,et al.  Collapsin response mediator protein-1 and the invasion and metastasis of cancer cells. , 2001, Journal of the National Cancer Institute.

[38]  E. Benarroch,et al.  CRMP‐5 neuronal autoantibody: Marker of lung cancer and thymoma‐related autoimmunity , 2001, Annals of neurology.

[39]  M. Noda,et al.  Molecular Characterization of CRMP5, a Novel Member of the Collapsin Response Mediator Protein Family* , 2000, The Journal of Biological Chemistry.

[40]  F. Knapp,et al.  Rhenium Radioisotopes for Therapeutic Radiopharmaceutical Development , 1999 .

[41]  S. Mirzadeh,et al.  Use of a new tandem cation/anion exchange system with clinical-scale generators provides high specific volume solutions of technetium-99m and rhenium-188 , 1998 .

[42]  S. Hockfield,et al.  TOAD-64, a gene expressed early in neuronal differentiation in the rat, is related to unc-33, a C. elegans gene involved in axon outgrowth , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[43]  S. Mirzadeh,et al.  Processing of reactor-produced 188W for fabrication of clinical scale alumina-based 188W/188Re generators , 1994 .

[44]  D. O'leary,et al.  Characterization of technetium-99m-L,L-ECD for brain perfusion imaging, Part 1: Pharmacology of technetium-99m ECD in nonhuman primates. , 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[45]  R A Holmes,et al.  Technetium-99 m d , l-HM-PAO : A New Rathopharmaceutical for SPECT Imaging of Regional CerebralBlood Perfusion , 2006 .

[46]  M. Divadeenam,et al.  Neutron resonance parameters and thermal cross sections , 1981 .

[47]  B. Rhodes.  Considerations in the radiolabeling of albumin. , 1974, Seminars in nuclear medicine.

[48]  O. W. Kolling.  Reduction of Perrhenate by Stannous Tin , 1954 .